Piper Sandler Maintains Overweight Rating for Poseida Therapeutics: Here's What You Need To Know

Piper Sandler Maintains Overweight Rating for Poseida Therapeutics: Here's What You Need To Know

 

Piper Sandler has decided to maintain its Overweight rating of Poseida Therapeutics PSTX and raise its price target from $9.00 to $11.00.

Shares of Poseida Therapeutics are trading up 1.08% over the last 24 hours, at $3.74 per share.

A move to $11.00 would account for a 194.12% increase from the current share price.

About Poseida Therapeutics

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: BZI-AAR-UPDATEAnalyst Ratings